Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

Efficacy of a Covalent ERK1/2 Inhibitor, CC-90003, in KRAS-Mutant Cancer Models Reveals Novel Mechanisms of Response and Resistance.

Aronchik I, Dai Y, Labenski M, Barnes C, Jones T, Qiao L, Beebe L, Malek M, Elis W, Shi T, Mavrommatis K, Bray GL, Filvaroff EH.

Mol Cancer Res. 2019 Feb;17(2):642-654. doi: 10.1158/1541-7786.MCR-17-0554. Epub 2018 Oct 1.

PMID:
30275173
2.

Phase I Study of CC-486 Alone and in Combination with Carboplatin or nab-Paclitaxel in Patients with Relapsed or Refractory Solid Tumors.

Von Hoff DD, Rasco DW, Heath EI, Munster PN, Schellens JHM, Isambert N, Tourneau CL, O'Neil B, Mathijssen RHJ, Lopez-Martin JA, Edenfield WJ, Martin M, LoRusso PM, Bray GL, DiMartino J, Nguyen A, Liu K, Laille E, Bendell JC.

Clin Cancer Res. 2018 Sep 1;24(17):4072-4080. doi: 10.1158/1078-0432.CCR-17-3716. Epub 2018 May 15.

PMID:
29764853
3.

Dulanermin with rituximab in patients with relapsed indolent B-cell lymphoma: an open-label phase 1b/2 randomised study.

Cheah CY, Belada D, Fanale MA, Janikova A, Czucman MS, Flinn IW, Kapp AV, Ashkenazi A, Kelley S, Bray GL, Holden S, Seymour JF.

Lancet Haematol. 2015 Apr;2(4):e166-74. doi: 10.1016/S2352-3026(15)00026-5. Epub 2015 Mar 25.

PMID:
26687959
4.

A randomized phase II trial of vismodegib versus placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated metastatic colorectal cancer.

Berlin J, Bendell JC, Hart LL, Firdaus I, Gore I, Hermann RC, Mulcahy MF, Zalupski MM, Mackey HM, Yauch RL, Graham RA, Bray GL, Low JA.

Clin Cancer Res. 2013 Jan 1;19(1):258-67. doi: 10.1158/1078-0432.CCR-12-1800. Epub 2012 Oct 18.

5.

Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A.

Tarantino MD, Collins PW, Hay CR, Shapiro AD, Gruppo RA, Berntorp E, Bray GL, Tonetta SA, Schroth PC, Retzios AD, Rogy SS, Sensel MG, Ewenstein BM; RAHF-PFM Clinical Study Group.

Haemophilia. 2004 Sep;10(5):428-37.

PMID:
15357767
6.

Antibodies to heterologous proteins in hemophilia A patients receiving recombinant factor VIII (Recombinate).

Ingerslev J, Christiansen K, Ravn HB, Bray GL, Gomperts ED; Recombinate Study Group.

Thromb Haemost. 2002 Apr;87(4):626-34.

PMID:
12008945
8.
9.

Multicenter trial to evaluate the safety and potential efficacy of pooled human fibrin sealant for the treatment of burn wounds.

Greenhalgh DG, Gamelli RL, Lee M, Delavari M, Lynch JB, Hansbrough JF, Achauer BM, Miller SF, MacPhee M, Bray GL.

J Trauma. 1999 Mar;46(3):433-40.

PMID:
10088846
10.

Comparison of high responder inhibitor frequency in recent studies of previously untreated patients with hemophilia A.

Ehrlich HJ, Bray GL, Gomperts ED.

Thromb Haemost. 1998 Jan;79(1):242-3. No abstract available.

PMID:
9459360
11.

A multicenter study of recombinant factor VIII (Recombinate(TM) ) in previously treated patients with hemophilia A.

White GC, Courter S, Bray GL, Lee M, Gomperts ED.

Haemophilia. 1997 Jul;3(3):232. doi: 10.1046/j.1365-2516.1997.t01-4-00125.x. No abstract available.

PMID:
27214819
12.
13.

Considerations governing factor IX product choice in hemophilia B.

Bray GL, Aledort LM.

Transfusion. 1994 Jun;34(6):554-5. No abstract available.

PMID:
8023402
14.

Erythropoietin response to critical illness.

Krafte-Jacobs B, Levetown ML, Bray GL, Ruttimann UE, Pollack MM.

Crit Care Med. 1994 May;22(5):821-6.

PMID:
8181291
15.

A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group.

Bray GL, Gomperts ED, Courter S, Gruppo R, Gordon EM, Manco-Johnson M, Shapiro A, Scheibel E, White G 3rd, Lee M.

Blood. 1994 May 1;83(9):2428-35.

16.

Assessing clinical severity in children with sickle cell disease. Preliminary results from a cooperative study.

Bray GL, Muenz L, Makris N, Lessin LS.

Am J Pediatr Hematol Oncol. 1994 Feb;16(1):50-4.

PMID:
8311173
18.

Loss of high-responder inhibitors in patients with severe hemophilia A and human immunodeficiency virus type 1 infection: a report from the Multi-Center Hemophilia Cohort Study.

Bray GL, Kroner BL, Arkin S, Aledort LW, Hilgartner MW, Eyster ME, Ragni MV, Goedert JJ.

Am J Hematol. 1993 Apr;42(4):375-9.

PMID:
8493988
19.
20.
21.

Splice junction mutations in factor IX gene resulting in severe hemophilia B.

Chen SH, Zhang M, Thompson AR, Bray GL, Scott CR.

Nucleic Acids Res. 1991 Mar 11;19(5):1172. No abstract available.

22.
23.

Recent advances in the preparation of plasma-derived and recombinant coagulation factor VIII.

Bray GL.

J Pediatr. 1990 Sep;117(3):503-7. Review. No abstract available.

PMID:
2118176
24.

Autoimmune thrombocytopenia in pediatric systemic lupus erythematosus: alternative therapeutic modalities.

Lipnick RN, Tsokos GC, Bray GL, White PH.

Clin Exp Rheumatol. 1990 May-Jun;8(3):315-9.

PMID:
1696192
25.

Idiopathic pulmonary hypertension, hemophilia A, and infection with human immunodeficiency virus (HIV)

Bray GL, Martin GR, Chandra R.

Ann Intern Med. 1989 Oct 15;111(8):689-90. No abstract available.

PMID:
2802426
26.
27.

Danazol fails to increase factor VIII or IX levels in a double-blind crossover study of patients with haemophilia A and B.

Nugent DJ, Bray GL, Counts RB, Clements MJ, Thompson AR.

Br J Haematol. 1986 Nov;64(3):493-502.

PMID:
3098273
28.
29.

Calcium-specific immunoassays for factor IX: reduced levels of antigen in patients with vitamin K disorders.

Bray GL, Weinmann AF, Thompson AR.

J Lab Clin Med. 1986 Mar;107(3):269-78.

PMID:
3485164
30.

Preoperative chemotherapy in the treatment of Wilms' tumor diagnosed with the aid of fine needle aspiration biopsy.

Bray GL, Pendergrass TW, Schaller RT Jr, Kiviat N, Beckwith JB.

Am J Pediatr Hematol Oncol. 1986 Spring;8(1):75-8. No abstract available.

PMID:
3013040
31.

An intragenic deletion of the factor IX gene in a family with hemophilia B.

Chen SH, Yoshitake S, Chance PF, Bray GL, Thompson AR, Scott CR, Kurachi K.

J Clin Invest. 1985 Dec;76(6):2161-4.

Supplemental Content

Support Center